{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:03:20Z","timestamp":1762866200390,"version":"build-2065373602"},"reference-count":99,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,5,26]],"date-time":"2013-05-26T00:00:00Z","timestamp":1369526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p>Rivaroxaban is the first agent available within a new class of anticoagulants called direct factor <jats:styled-content style=\"fixed-case\">X<\/jats:styled-content>a inhibitors. Rivaroxaban is approved for use in the <jats:styled-content style=\"fixed-case\">U<\/jats:styled-content>nited <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tates for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the prevention of deep vein thrombosis in patients undergoing total hip replacement and total knee replacement, for the treatment of deep vein thrombosis and pulmonary embolism, and for the reduction in risk of recurrence of deep vein thrombosis and pulmonary embolism (with additional indications under review). Rivaroxaban dose and frequency of administration vary depending on the indication. As of result of predictable pharmacokinetics and pharmacodynamics, a fixed dose of rivaroxaban is administered without routine coagulation testing. Rivaroxaban has a short half\u2010life, undergoes a dual mode of elimination (hepatic and renal), and is a substrate for <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\u2010glycoprotein. Rivaroxaban has a lower potential for drug interactions compared with warfarin. Despite the advantages of a once\/day fixed\u2010dose oral agent, in many clinical situations limited evidence is available to guide optimal management of rivaroxaban therapy. In this article, we review the available evidence and provide recommendations where possible for such situations including the desire to monitor the anticoagulation intensity, use in special patient populations, managing drug interactions, and transitioning across anticoagulant agents. Potential strategies for reversing rivaroxaban's anticoagulant effect are reviewed. Health systems will need to perform a systematic safety evaluation and ensure that numerous hospital policies related to anticoagulation are updated to include rivaroxaban. A comprehensive approach to education is needed for clinicians, patients, and technical support personnel involved in patient interactions to ensure safe use.<\/jats:p>","DOI":"10.1002\/phar.1289","type":"journal-article","created":{"date-parts":[[2013,5,27]],"date-time":"2013-05-27T00:31:50Z","timestamp":1369614710000},"page":"1223-1245","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy"],"prefix":"10.1002","volume":"33","author":[{"given":"Maureen A.","family":"Smythe","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Wayne State University Detroit Michigan"},{"name":"Department of Pharmaceutical Services Beaumont Hospital Royal Oak Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Gulseth","sequence":"additional","affiliation":[{"name":"Sanford University of South Dakota Medical Center Sioux Falls South Dakota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann K.","family":"Wittkowsky","sequence":"additional","affiliation":[{"name":"University of Washington Medical Center Seattle Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Spinler","sequence":"additional","affiliation":[{"name":"Philadelphia College of Pharmacy University of the Sciences in Philadelphia Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Dager","sequence":"additional","affiliation":[{"name":"Davis Medical Center University of California Sacremento California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith A.","family":"Nutescu","sequence":"additional","affiliation":[{"name":"College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,5,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00458.x"},{"key":"e_1_2_8_3_1","first-page":"527","article-title":"Characteristics of novel anticoagulants and potential economic implications","volume":"17","author":"Nutescu E","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-07-0434"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0549-x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03759.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.79"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04098.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1301415"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-03-0176"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4065\/82.7.864"},{"key":"e_1_2_8_22_1","unstructured":"U.S. Food and Drug Administration.Briefing information for the cardiovascular and renal drugs advisory committee (CRDAC) May 23 2012 meeting. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeeting Materials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM304755.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11595320-000000000-00000"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-01-0080"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23208"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-08-0511"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.01.001"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0328"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0667"},{"key":"e_1_2_8_30_1","unstructured":"U.S. Food and Drug Administration.FDA draft briefing document for the cardiovascular and renal drugs advisory committee (CRDAC) meeting September 8 2011. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM270796.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f2f264"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847030-00006"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23165"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e328349f1d6"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0622-5"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-03-0204"},{"issue":"2","key":"e_1_2_8_37_1","first-page":"PP\u2010MO\u2010185","article-title":"Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"5","author":"Perzborn E","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-06-0391"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04784.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.05.010"},{"key":"e_1_2_8_41_1","unstructured":"Bayer Canada. Xarelto Product Monograph. Available fromhttp:\/\/www.bayer.ca\/files\/XARELTO-PM-ENG-18JUL2012-154961.pdf?#. Accessed January 22 2013."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.12.1175"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03753.x"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-12-0714"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04181.x"},{"key":"e_1_2_8_46_1","unstructured":"U.S. Food and Drug Administration.Xarelto Prescribing Information. Available fromhttp:\/\/www.xareltohcp.com\/sites\/default\/files\/pdf\/xarelto_0.pdf#zoom=100. Accessed March 27 2013."},{"key":"e_1_2_8_47_1","unstructured":"European Medicines Association.Xarelto EPAR Product Information. Available fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/000944\/WC500057108.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V112.11.436.436","article-title":"Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery","volume":"112","author":"Bauer KA","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr342"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_2_8_53_1","first-page":"340\u20107 e1","article-title":"Rivaroxaban\u2010once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"The Executive Steering Committee on behalf of the ROCKET\u2010AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.057"},{"key":"e_1_2_8_55_1","unstructured":"Janssen Pharmaceuticals.Data on File. Xarelto temporary interruption in ROCKET\u2010AF. Titusville NJ;2012."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0209"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-378950"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210793563338"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2298"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0b013e3181c15c70"},{"key":"e_1_2_8_61_1","unstructured":"Janssen Research & Development LLC.Advisory committee briefing document. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM304757.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_62_1","unstructured":"U. S. Food and Drug Administration.Briefing information for the March 19 2009 meeting of the cardiovascular and renal drugs advisory committee. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM181524.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_63_1","unstructured":"Johnson & Johnson Pharmaceutical Research & Development.Advisory Committee Briefing Book. Prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip replacement or knee replacement surgery. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM138385.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23202"},{"key":"e_1_2_8_66_1","first-page":"P\u2010W\u2010652","article-title":"Recombinant factor VIIa partially reverses the anticoagulant effect of high\u2010dose rivaroxaban a novel, oral, direct factor Xa inhibitor in rats","volume":"5","author":"Tinel H","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_67_1","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood.V112.11.3825.3825","article-title":"Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates","volume":"112","author":"Gruber A","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318238c036"},{"issue":"2","key":"e_1_2_8_69_1","first-page":"PP\u2010MO\u2010183","article-title":"Prothrombin complex concentrate reverses the effects of high\u2010dose rivaroxaban in rats","volume":"379","author":"Perzborn ETA","year":"2009","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0179"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.300053"},{"key":"e_1_2_8_73_1","unstructured":"U.S. Food and Drug Administration.Drug development and drug interactions: table of substrates inhibitors and inducers. Available fromhttp:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm#inhibitors. Accessed January 22 2013."},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02776.x"},{"key":"e_1_2_8_75_1","first-page":"e185","article-title":"The relative bioavailability of a single\u2010dose rivaroxaban, a novel oral anticoagulant and selective direct factor Xa inhibitor, administered orally (as a whole or crushed tablet) and via nasogastric tube (as a crushed tablet suspension) (abstract 28)","volume":"32","author":"Moore KT","year":"2012","journal-title":"Pharmacotherapy"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2302"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-010-9539-8"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.12.014"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.008"},{"key":"e_1_2_8_81_1","unstructured":"ATLAS ACS\u2010TIMI 51 protocol. Available fromhttp:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1112277\/suppl_file\/nejmoa1112277_protocol.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0262"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296058"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0601"},{"key":"e_1_2_8_87_1","unstructured":"ClinicalTrials.gov.Switching Study from Warfarin to Rivaroxaban. Available fromhttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01507051?term=rivaroxaban&rank=2. Accessed January 22 2013."},{"key":"e_1_2_8_88_1","unstructured":"ClinicalTrials.gov.A study to explore the pharmacodynamic changes when transitioning from rivaroxaban to warfarin in healthy volunteers. Available fromhttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01400646?term=NCT01400646&rank=1. Accessed January 22 2013."},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R634"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.2044"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0690-1"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L098"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.239"},{"volume-title":"Cardiology secrets","year":"2013","author":"Spinler SA","key":"e_1_2_8_94_1"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.5.565"},{"key":"e_1_2_8_96_1","unstructured":"Xarelto CarePath.Supporting your journey. Available fromhttp:\/\/www.xareltocarepath.com. Accessed January 22 2013."},{"key":"e_1_2_8_97_1","unstructured":"U.S. Food and Drug Administration.Approved Risk Evaluation and Mitigation Strategy. Xarelto (rivaroxaban) tablets risk and mitigation strategy. Available fromhttp:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM295405.pdf. Accessed January 22 2013."},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5603"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03989.x"},{"key":"e_1_2_8_100_1","unstructured":"Xarelto (rivaroxaban tablets) Prescribing Information. Janssen Pharmaceuticals Inc. Titusville NJ; March2013. Available fromhttp:\/\/www.xareltohcp.com\/sites\/default\/files\/pdf\/xarelto_0.pdf#zoom=100. Accessed March 25 2013."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1289","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:59Z","timestamp":1761052319000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,26]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/phar.1289"],"URL":"https:\/\/doi.org\/10.1002\/phar.1289","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2013,5,26]]},"assertion":[{"value":"2013-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}